Cipla, Boehringer Ingelheim To Co-Market 3 Oral Anti-Diabetic Drugs
The three drugs are Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
Jun 29, 2020 / 03:30 PM IST
Cipla and Boehringer Ingelheim (India) on June 29 announced a partnership to co-market three new oral anti-diabetic drugs — Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
According to the International Diabetes Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045.
"Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care," Cipla India Business Executive VP & CEO Nikhil Chopra said.
Also Read | Mylan's imports containing raw material for Remdesivir stuck at Mumbai Air Cargo: Report
In a similar vein, Boehringer Ingelheim India MD Sharad Tyagi said: "As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive diabetes portfolios in the country".
Oboravo is approved for glucose-control in patients with type-2 diabetes. It is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease, it added.
While Oboravo Met can be given to newly diagnosed patients of type-2 diabetes who have higher baseline HbA1c levels, Tiptengio is the world's first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor, the statement said.
(With PTI inputs)
Follow our coverage of the coronavirus crisis here